Advertisement

Follow us on Twitter @CIR_AACR!

From the Current Issue

  • Research Articles | AuthorChoice
    Disrupting LILRB4/APOE Interaction by an Efficacious Humanized Antibody Reverses T-cell Suppression and Blocks AML Development
    Xun Gui, Mi Deng, Hao Song, Yuanzhi Chen, Jingjing Xie, Zunling Li, Licai He, Fangfang Huang, Yixiang Xu, Yasuaki Anami, Hai Yu, Chenyi Yu, Leike Li, Zihao Yuan, Xiaoying Xu, Qihui Wang, Yan Chai, Tao Huang, Yi Shi, Kyoji Tsuchikama, X. Charlene Liao, Ningshao Xia, George F. Gao, Ningyan Zhang, Cheng Cheng Zhang and Zhiqiang An
    Cancer Immunol Res August 1 2019 7 (8) 1244-1257; DOI:10.1158/2326-6066.CIR-19-0036

    When LILRB4 on acute myeloid leukemia cells (AML) binds to its ligand APOE, T-cell activation is suppressed. A humanized mAb to LILRB4 blocks LILRB4/APOE interaction and, through multiple modes of action, blocks AML development in mouse models.

  • Research Articles | AuthorChoice
    Enriched HLA-E and CD94/NKG2A Interaction Limits Antitumor CD8+ Tumor-Infiltrating T Lymphocyte Responses
    Megat Abd Hamid, Ruo-Zheng Wang, Xuan Yao, Peiwen Fan, Xi Li, Xue-Mei Chang, Yaning Feng, Stephanie Jones, David Maldonado-Perez, Craig Waugh, Clare Verrill, Alison Simmons, Vincenzo Cerundolo, Andrew McMichael, Christopher Conlon, Xiyan Wang, Yanchun Peng and Tao Dong
    Cancer Immunol Res August 1 2019 7 (8) 1293-1306; DOI:10.1158/2326-6066.CIR-18-0885

    Enriched HLA-E expression on carcinomas and tumor-associated macrophages and DCs correlated with coexpression of the CD94/NKG2A inhibitory receptor on PD-1hi TILs. These TILs had impaired responses to IL2 and poor effector function, contributing to immune evasion of tumors.

  • Research Articles
    Histone Deacetylase Inhibition Sensitizes PD1 Blockade–Resistant B-cell Lymphomas
    Xiaoguang Wang, Brittany C. Waschke, Rachel A. Woolaver, Zhangguo Chen, Gan Zhang, Anthony D. Piscopio, Xuedong Liu and Jing H. Wang
    Cancer Immunol Res August 1 2019 7 (8) 1318-1331; DOI:10.1158/2326-6066.CIR-18-0875

    The isoform-selective histone-deacetylase inhibitor OKI-179 has promising pharmacokinetics and immune enhancing effects. Combined treatment with OKI-179/anti-PD1 effectively inhibited poorly immunogenic B-cell lymphomas, providing a rationale for developing combinatorial therapy using epigenetic agents with immune checkpoint inhibitors.

OnlineFirst Articles

Load more
Advertisement

Back to top